Literature DB >> 34705554

Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung Infection.

Lokesh Sharma1, Xiaohua Peng1,2, Hua Qing3,4, Brandon K Hilliard3,4, Jooyoung Kim1, Anush Swaminathan3,4, Justin Tian3,4, Kavita Israni-Winger3,4, Cuiling Zhang3,4, Victoria Habet5, Lin Wang1, Gayatri Gupta1, Xuefei Tian6, Yina Ma7, Hyeon-Jun Shin1, Sang-Hun Kim1, Min-Jong Kang1, Shuta Ishibe6, Lawrence H Young7, Sergei Kotenko8, Susan Compton9, Craig B Wilen4,10, Andrew Wang3,4, Charles S Dela Cruz1,11,12.   

Abstract

Coronaviruses are a major health care threat to humankind. Currently, the host factors that contribute to limit disease severity in healthy young patients are not well defined. Interferons are key antiviral molecules, especially type I and type III interferons. The role of these interferons during coronavirus disease is a subject of debate. Here, using mice that are deficient in type I (IFNAR1-/-), type III (IFNLR1-/-), or both (IFNAR1/LR1-/-) interferon signaling pathways and murine-adapted coronavirus (MHV-A59) administered through the intranasal route, we define the role of interferons in coronavirus infection. We show that type I interferons play a major role in host survival in this model, while a minimal role of type III interferons was manifested only in the absence of type I interferons or during a lethal dose of coronavirus. IFNAR1-/- and IFNAR1/LR1-/- mice had an uncontrolled viral burden in the airways and lung and increased viral dissemination to other organs. The absence of only type III interferon signaling had no measurable difference in the viral load. The increased viral load in IFNAR1-/- and IFNAR1/LR1-/- mice was associated with increased tissue injury, especially evident in the lung and liver. Type I but not type III interferon treatment was able to promote survival if treated during early disease. Further, we show that type I interferon signaling in macrophages contributes to the beneficial effects during coronavirus infection in mice. IMPORTANCE The antiviral and pathological potential of type I and type III interferons during coronavirus infection remains poorly defined, and opposite findings have been reported. We report that both type I and type III interferons have anticoronaviral activities, but their potency and organ specificity differ. Type I interferon deficiency rendered the mice susceptible to even a sublethal murine coronavirus infection, while the type III interferon deficiency impaired survival only during a lethal infection or during a sublethal infection in the absence of type I interferon signaling. While treatment with both type I and III interferons promoted viral clearance in the airways and lung, only type I interferons promoted the viral clearance in the liver and improved host survival upon early treatment (12 h postinfection). This study demonstrates distinct roles and potency of type I and type III interferons and their therapeutic potential during coronavirus lung infection.

Entities:  

Keywords:  antiviral agents; coronavirus; lung defense; type I interferons; type III interferons

Mesh:

Substances:

Year:  2021        PMID: 34705554      PMCID: PMC8791255          DOI: 10.1128/JVI.01241-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  48 in total

Review 1.  Antiviral interferon response at single-cell resolution.

Authors:  Soheil Rastgou Talemi; Thomas Höfer
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

Review 2.  Alpha-interferon treatment in hepatitis B.

Authors:  Aaron Shu Jeng Woo; Raymond Kwok; Taufique Ahmed
Journal:  Ann Transl Med       Date:  2017-04

3.  Targeted disruption of the Ceacam1 (MHVR) gene leads to reduced susceptibility of mice to mouse hepatitis virus infection.

Authors:  D M Blau; C Turbide; M Tremblay; M Olson; S Létourneau; E Michaliszyn; S Jothy; K V Holmes; N Beauchemin
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 4.  Shared and Distinct Functions of Type I and Type III Interferons.

Authors:  Helen M Lazear; John W Schoggins; Michael S Diamond
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

Review 5.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.

Authors:  Roland Züst; Ying-Xiu Toh; Iris Valdés; Daniela Cerny; Julia Heinrich; Lisset Hermida; Ernesto Marcos; Gerardo Guillén; Ulrich Kalinke; Pei-Yong Shi; Katja Fink
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

Review 7.  Herd Immunity: Understanding COVID-19.

Authors:  Haley E Randolph; Luis B Barreiro
Journal:  Immunity       Date:  2020-05-19       Impact factor: 31.745

8.  Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice.

Authors:  Fatai S Oladunni; Jun-Gyu Park; Paula A Pino; Olga Gonzalez; Anwari Akhter; Anna Allué-Guardia; Angélica Olmo-Fontánez; Shalini Gautam; Andreu Garcia-Vilanova; Chengjin Ye; Kevin Chiem; Colwyn Headley; Varun Dwivedi; Laura M Parodi; Kendra J Alfson; Hilary M Staples; Alyssa Schami; Juan I Garcia; Alison Whigham; Roy Neal Platt; Michal Gazi; Jesse Martinez; Colin Chuba; Stephanie Earley; Oscar H Rodriguez; Stephanie Davis Mdaki; Katrina N Kavelish; Renee Escalona; Cory R A Hallam; Corbett Christie; Jean L Patterson; Tim J C Anderson; Ricardo Carrion; Edward J Dick; Shannan Hall-Ursone; Larry S Schlesinger; Xavier Alvarez; Deepak Kaushal; Luis D Giavedoni; Joanne Turner; Luis Martinez-Sobrido; Jordi B Torrelles
Journal:  Nat Commun       Date:  2020-11-30       Impact factor: 14.919

9.  Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.

Authors:  Jennifer S Chen; Mia Madel Alfajaro; Ryan D Chow; Jin Wei; Renata B Filler; Stephanie C Eisenbarth; Craig B Wilen
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

View more
  2 in total

1.  Coronavirus Lung Infection Impairs Host Immunity against Secondary Bacterial Infection by Promoting Lysosomal Dysfunction.

Authors:  Xiaohua Peng; Jooyoung Kim; Gayatri Gupta; Karen Agaronyan; Madeleine C Mankowski; Asawari Korde; Shervin S Takyar; Hyeon Jun Shin; Victoria Habet; Sarah Voth; Jonathon P Audia; Xinran Liu; Lin Wang; Ying Cai; Xuefei Tian; Shuta Ishibe; Min-Jong Kang; Susan Compton; Craig B Wilen; Charles S Dela Cruz; Lokesh Sharma
Journal:  J Immunol       Date:  2022-09-02       Impact factor: 5.426

2.  Priming With Rhinovirus Protects Mice Against a Lethal Pulmonary Coronavirus Infection.

Authors:  Garrison Cox; Andres J Gonzalez; Emmanuel C Ijezie; Andres Rodriguez; Craig R Miller; James T Van Leuven; Tanya A Miura
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.